Drug Profile
BMS 933043
Alternative Names: BMS-933043Latest Information Update: 29 Aug 2014
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antidementias; Antipsychotics
- Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Schizophrenia
Most Recent Events
- 10 Jul 2014 Discontinued - Phase-I for Schizophrenia (In volunteers) in USA (PO)
- 31 Dec 2013 Bristol-Myers Squibb completes a phase I trial in Healthy volunteers in USA (NCT01605994)
- 01 Dec 2013 Bristol-Myers Squibb completes enrolment in its phase I trial in Healthy volunteers in USA (NCT01605994)